MHRA Enforcement Operations 2025-26: What the Releases Say

What do the MHRA's own press releases from October 2025 to July 2026 actually record about illegal manufacturing sites, seizures and 'peptide products', and how does that differ from the separate April 2026 clinic inquiry?

Between October 2025 and July 2026 the Medicines and Healthcare products Regulatory Agency published four releases on GOV.UK about its Criminal Enforcement Unit's work against illegal supply of GLP-1-class medicines. Three describe raids on suspected manufacturing or distribution sites. The fourth is a consumer warning. Two of the raid releases use the phrase "peptide products", and none defines it ^[2][3].

None of them is the April 2026 inquiry into clinics, which concerns the claims clinics make. This article sets the four releases out as a dated record, says what each states, and says what none of them states. It does not repeat vendor commentary, and where a claim rests on trade press alone it says so.

Two tracks that are often conflated

The first track is the clinic inquiry. In April 2026, trade and national press reported that the MHRA was looking at UK clinics that described experimental peptide injections in health terms. That reporting is secondary, and the inquiry turns on how products are presented. It is covered in a separate article on this site and is outside the four releases here.

The second track is criminal enforcement. The Criminal Enforcement Unit investigates the manufacture and supply of medicines without the required authorisation. The releases below describe that work. They are about sites, equipment, ingredients and finished product, and about named compounds that are prescription medicines or that, in one case, the MHRA says has not been approved for UK use ^[1].

Running the two together produces the common error of reading the raids as a statement about all peptide supply. The releases do not support that reading.

24 October 2025: Northampton

The first release, published on 24 October 2025, describes a two-day search of a warehouse on an industrial estate on the outskirts of Northampton ^[1]. The seizure included tens of thousands of empty pens, raw chemical ingredients, packaging and manufacturing equipment, more than two thousand finished pens awaiting dispatch with an estimated value over £250,000, and about £20,000 in cash suspected to be linked to medicines trafficking ^[1].

The release names retatrutide and tirzepatide as the compounds in question. Its notes say the MHRA's financial investigators are authorised by the National Crime Agency under the Proceeds of Crime Act 2002, and that retatrutide has not been approved for UK use ^[1]. It quotes the head of the Criminal Enforcement Unit as saying prescription medicines should only be obtained from a registered pharmacy ^[1].

Two points are worth stating plainly. The release does not mention arrests. And the phrase "peptide products" does not appear in it ^[1].

25 February 2026: Sleaford and Grantham

The second release, published on 25 February 2026, says officers searched a farm near Sleaford and a residential address in Grantham earlier that week, in an operation covering Lincolnshire and Nottinghamshire ^[2]. It records almost two thousand finished items awaiting dispatch, manufacturing equipment, suspected pharmaceutical ingredients, packaging and commercial vehicles ^[2].

This is the first release in the series to use the phrase. It says the premises are believed to have been used for manufacturing and distributing unlicensed medicines "including retatrutide and tirzepatide, as well as peptide products" ^[2]. It does not describe those peptide products, say what they are for, or say whether any were among the items seized. No arrests are mentioned ^[2].

29 May 2026: an estate near Northampton

The third release, published on 29 May 2026, describes a raid on the night of 28 May at a country estate near Northampton, supported by Northamptonshire Police ^[3]. The MHRA calls it its largest ever seizure of unlicensed medicines of this type and puts the figure at about twelve thousand finished items, together with substantial packaging and substances believed to be used in illicit manufacturing ^[3].

Two men, both aged 29, were arrested on suspicion of offences under the Human Medicines Regulations 2012, and enquiries were said to be continuing ^[3]. The release lists "peptide products" alongside the two named compounds as items the property was believed to manufacture, assemble and distribute. Again it does not say which peptides ^[3].

24 July 2026: the consumer warning

The fourth release, dated 24 July 2026, is a different kind of document. It is aimed at the public and advises against buying prescription GLP-1 medicines from unregulated websites or social media sellers, because fake products may contain other substances, including toxic ones ^[4]. It names several authorised brands and notes that retatrutide is not authorised for use in the UK ^[4].

It reports no raid and no arrest, and it does not mention peptides ^[4]. It belongs in the record because it states the regulator's consumer-facing position on the illegal online market that the raids concern.

What "peptide products" means in the releases

The honest answer is that the releases do not say. The phrase appears twice, in a sentence listing what a site was believed to make or distribute, after two named prescription-medicine compounds ^[2][3]. It is not defined, no peptide is named, and no release says that any such product was found.

Several readings are possible, and the releases support none of them over the others. It might describe products presented as peptides that contained one of the named compounds. It might describe separate products. It might be a general label used by the investigators. Anyone who tells you with confidence what the MHRA meant is supplying their own interpretation.

The legal basis

The only statute the releases name is the Human Medicines Regulations 2012, in the arrest wording of the May release ^[3]. Those Regulations set out when a product is a medicinal product and what authorisation is needed to make, sell or supply it ^[5]. The October release adds the Proceeds of Crime Act 2002 as the basis for the MHRA's financial investigators ^[1].

The releases do not explain how the Regulations apply to each seized item, and they should not be read as a legal analysis. Arrest on suspicion is not a finding that an offence was committed. For the way the Regulations treat products according to how they are presented, see the companion article on the 2012 Regulations and peptides.

What a research supplier can and cannot read into these operations

The releases describe sites suspected of manufacturing and distributing finished GLP-1-class medicines, including pens, and of doing so without authorisation. They do not describe laboratory supply of research materials, and they say nothing about research-use labelling.

What a careful reader can take from them is limited, and worth stating. The Criminal Enforcement Unit is active. The agency has used the phrase "peptide products" in two of its releases and has not defined it. And the legal question in each case is whether a product is an unauthorised medicine. That question turns on what a product is and how it is presented and supplied, and a document alone does not settle it.

A purchaser can respond in practical terms. Keep documentation that shows what a material is and where it came from. Do not rely on a vendor's description of the regulator's position. And read these releases themselves, including the wider 2026 story for context that the releases do not give.

What to check next

Open the four GOV.UK releases cited here and read them against any summary you have been given. They were read on 10 October 2026 for this article. The MHRA publishes further releases, so check the agency's news page for anything dated later than 24 July 2026 before relying on this record as complete.